ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

PRLD Prelude Therapeutics Inc

4.07
0.03 (0.74%)
26 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Prelude Therapeutics Inc PRLD NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.03 0.74% 4.07 23:00:02
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
4.04 3.99 4.07 4.07 4.04
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
09/4/202415:35GLOBEPrelude Highlights Continued Strength of Discovery Engine at..
05/3/202415:45GLOBEPrelude Announces Acceptance of Multiple Preclinical..
04/3/202417:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202417:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202417:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202417:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202416:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202415:05GLOBEPrelude Therapeutics to Participate in Barclays Global..
15/2/202416:22EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
15/2/202415:22EDGAR2Form 8-K - Current report
15/2/202415:05GLOBEPrelude Therapeutics Reports Full Year 2023 Financial..
12/2/202415:26EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08/1/202416:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/12/202308:34GLOBEPrelude Therapeutics Announces $25 Million Private Placement
11/12/202308:17EDGAR2Form 8-K - Current report
01/11/202315:37EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/11/202315:23EDGAR2Form 8-K - Current report
01/11/202315:10GLOBEPrelude Announces Strategic Pipeline Progress and Updates,..
01/11/202315:05GLOBEPrelude Therapeutics and AbCellera Enter Partnership to..
14/10/202311:30GLOBEPrelude Announces Multiple Clinical and Preclinical Poster..
06/10/202308:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/8/202307:30GLOBEPrelude Therapeutics to Participate in Three Healthcare..
03/8/202307:14EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/8/202307:10EDGAR2Form 8-K - Current report
03/8/202307:00GLOBEPrelude Therapeutics Announces Second Quarter 2023 Financial..
06/7/202315:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/5/202307:30GLOBEPrelude Therapeutics To Participate in Jefferies Healthcare..
18/5/202306:00GLOBEPrelude Therapeutics Announces Pricing of Public Offering
17/5/202315:08GLOBEPrelude Therapeutics Announces Launch of Proposed Public..
08/5/202307:30GLOBEPrelude Therapeutics Announces First Quarter 2023 Financial..

Su Consulta Reciente

Delayed Upgrade Clock